What Is Chonluten?
Chonluten is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the family of short peptide bioregulators designed to selectively restore gene expression in specific tissue types — in Chonluten’s case, the bronchial and alveolar epithelium of the lungs. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Khavinson’s group identified that short di- to tetrapeptides derived from tissue-specific organ extracts retain the capacity to interact with complementary DNA sequences and modulate gene transcription relevant to the organ of origin. Chonluten was isolated and synthesized from lung tissue fractions and has been studied primarily in the context of chronic respiratory disease, age-related pulmonary decline, and post-infection lung tissue restoration.
Research use is conducted under RUO (Research Use Only) conditions. Chonluten is not approved as a therapeutic agent in the United States or the European Union.
Mechanism of Action
Chonluten’s proposed mechanism centers on epigenetic and transcriptional regulation within bronchial and alveolar epithelial cells. The tetrapeptide sequence Ala-Glu-Asp-Leu carries a charge distribution that facilitates interaction with histones and promoter regions of genes governing cell cycle regulation, inflammatory signaling, and extracellular matrix maintenance in pulmonary tissue.
Khavinson’s laboratory reported that tetrapeptide bioregulators of this class bind to double-stranded DNA at complementary purine-pyrimidine sequences, functioning as sequence-specific regulators of chromatin structure. In pulmonary cells, Chonluten has been proposed to upregulate genes involved in mucociliary clearance, alveolar surfactant production, and anti-oxidant defenses, while modulating NF-κB-mediated pro-inflammatory cytokine production.
Preclinical data suggest effects on bronchial smooth muscle relaxation and on slowing the fibrotic remodeling pathways implicated in COPD and idiopathic pulmonary fibrosis (IPF). These findings remain preliminary and are derived primarily from Russian institutional research.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Peptide regulation of gene expression and protein synthesis in bronchial epithelium
Khavinson VKh, Grigoriev EI, Malinin VV, et al. Bulletin of Experimental Biology and Medicine. 2003. - Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG. Neuroendocrinology Letters. 2003;24(3–4):233–240. - Peptide bioregulators and aging
Khavinson VKh, Anisimov VN. Biogerontology. 2008. - Peptide AEDL alters gene expression in human lung fibroblasts
Ashapkin VV, Kutueva LI, Vanyushin BF, Khavinson VKh. Biochemistry (Moscow). 2021;86(4). - Khavinson development attribution. Avolio et al. Int J Mol Sci. 2022;23(7):3607. Khavinson peptide attribution.
Chonluten is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the family of short peptide bioregulators designed to selectively restore gene expression in specific tissue types — in Chonluten’s case, the bronchial and alveolar epithelium of the lungs.